Early Prediction of Outcomes in Adults With Recent-Onset Inflammatory Polyarthritis Using Established and New Predictors

What this Trial Is About

Researchers are studying patients with early polyarthritis, including rheumatoid arthritis RA, which is a common inflammatory joint disease causing disability and high costs. The trial aims to evaluate specific antibodies and other markers to predict which patients will have persistent or severe disease, helping doctors make better treatment decisions. This study focuses on patients with symptoms lasting less than 12 months to understand disease progression over time. This is a long-term observational study that follows about 390 adults with recent-onset inflammatory polyarthritis. Patients are regularly assessed over five years with blood tests, genetic analyses, and clinical evaluations. The study does not interfere with usual treatment. Researchers measure the presence of rheumatoid arthritis-specific autoantibodies, genetic markers, and other biological indicators to predict disease severity and treatment needs. Participants will undergo regular visits to collect clinical, serological, radiological, and genetic data at defined intervals up to 60 months after symptom onset. The study tracks disease persistence, severity using radiographic scores, and treatment use including advanced therapies. Psychosocial factors are also evaluated annually. This approach helps understand prognosis and guides future clinical care for early inflammatory arthritis patients.

Prognostic Evaluation of Inflammatory Polyarthritis of Recent Onset